NEJM AI to Educate Clinicians about Artificial Intelligence Applications in Medicine

NEJM Group, publisher of the New England Journal of Medicine, today announced the launch of its newest title, NEJM AI, a peer-reviewed, monthly journal dedicated to the latest research and application of artificial intelligence (AI) and machine learning in medicine. In addition to original research articles, the journal publishes reviews, policy perspectives and educational material for clinicians, scientists, health care leaders, policy makers, regulators, and executives with pharmaceutical, device-manufacturing and technology companies. Benchmark data sets and protocols are a unique feature of the journal and are freely available to practitioners to help with testing and advancing medical AI knowledge.

"What many people don’t know is that AI is already being used in medicine," said Eric Rubin, M.D., Ph.D., editor-in-chief of the New England Journal of Medicine and NEJM Group publications. "Our newest peer-reviewed journal, NEJM AI, will cover this rapidly changing field to deliver trusted, high-quality evidence and educational material to clinicians with the aim of improving health care for patients worldwide."

In the past decade, the Food and Drug Administration has approved AI-powered devices capable of reading medical imaging and assisting clinicians in making diagnoses. While many of these devices and programs meet regulatory standards, the medical community has been slow to see the potential of AI medical applications or adopt them. NEJM AI aims to be an essential resource for medical professionals who want an in-depth understanding of how breakthrough clinical applications in AI/ML will be evaluated to inform clinical practice.

"We're at a pivotal time in medicine with a new participant in medical decision making," said NEJM AI editor-in-chief, Isaac (Zak) Kohane, M.D., Ph.D. "AI is not a fad. It will revolutionize the way medicine is practiced and change the doctor-patient relationship. NEJM AI will apply the same rigorous standards as our flagship journal to determine which AI tools are ready for use in medical settings." Additional insights from Dr. Kohane and the editors are provided in these editorials by Kohane and Koller.

According to Statista, the market for AI in healthcare in 2021 was $11 billion (USD) worldwide, with that number expected to reach $188 billion by 2030. "With such growth, it's important that AI tools meet the same bar for medical evidence that is expected from other clinical interventions," said Charlotte Haug, M.D., Ph.D., Executive Editor of NEJM AI. "Our editorial team of clinical and biomedical informatics experts seeks to publish the most important trials designed to test an AI tool against an established standard, meeting high safety standards."

Community members are encouraged to listen to NEJM AI Grand Rounds, a podcast hosted by deputy editors Arjun (Raj) Manrai, Ph.D. and Andrew Beam, Ph.D., featuring informal conversations with experts exploring issues at the intersection of artificial intelligence, machine learning, and medicine. The journal also hosts virtual events to open dialogue around the value, ethics, and quality of medical AI.

NEJM AI will provide a range of perspectives on the critical ethical and legal challenges and risks around the development and deployment of AI in a clinical setting. Stimulating conversations among clinicians who use medical AI, developers of the technology, and patients who benefit from these applications is the mission of NEJM AI. Researchers are invited to submit their manuscripts for consideration or email This email address is being protected from spambots. You need JavaScript enabled to view it. with questions for the editors. Those with an interest in keeping abreast of this rapidly changing field may sign up for the newsletter or subscribe to NEJM AI.

About NEJM Group

NEJM Group creates high-quality medical resources for research, learning, practice and professional development designed to meet the demand for essential medical knowledge among academic researchers and teachers, physicians, clinicians, executives and others in medicine and health care. NEJM Group products include the New England Journal of Medicine, NEJM Evidence, NEJM AI, NEJM Catalyst, NEJM Journal Watch, NEJM Knowledge+, NEJM Healer, NEJM Resident 360, NEJM Yi Xue Qian Yan and NEJM Career Center. NEJM Group is a division of the Massachusetts Medical Society. For more information visit www.nejmgroup.org.

About NEJM AI

NEJM AI is an interdisciplinary journal that bridges fast-moving developments in AI, informatics, and technology in medicine with the application of these advancements to clinical practice. NEJM AI covers the application of AI methodologies and data science to biomedical informatics, connected health, telemedicine, medical images and imaging, personalized medicine, policy and regulation, and the ethical and medicolegal implications of AI. Visit https://ai.nejm.org for more details.

Most Popular Now

Most Advanced Artificial Touch for Brain…

For the first time ever, a complex sense of touch for individuals living with spinal cord injuries is a step closer to reality. A new study published in Science, paves...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

Using AI to Uncover Hospital Patients�…

Across the United States, no hospital is the same. Equipment, staffing, technical capabilities, and patient populations can all differ. So, while the profiles developed for people with common conditions may...

New AI Tool Uses Routine Blood Tests to …

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of...

New Method Tracks the 'Learning Cur…

Introducing Annotatability - a powerful new framework to address a major challenge in biological research by examining how artificial neural networks learn to label genomic data. Genomic datasets often contain...

Picking the Right Doctor? AI could Help

Years ago, as she sat in waiting rooms, Maytal Saar-Tsechansky began to wonder how people chose a good doctor when they had no way of knowing a doctor's track record...

From Text to Structured Information Secu…

Artificial intelligence (AI) and above all large language models (LLMs), which also form the basis for ChatGPT, are increasingly in demand in hospitals. However, patient data must always be protected...

AI Innovation Unlocks Non-Surgical Way t…

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients’ cancer without aggressive surgery. The proof-of-concept study, co-led...

Deep Learning Model Helps Detect Lung Tu…

A new deep learning model shows promise in detecting and segmenting lung tumors, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA)...

One of the Largest Global Surveys of Soc…

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch...

New Study Reveals AI's Transformati…

Intensive care units (ICUs) face mounting pressure to effectively manage resources while delivering optimal patient care. Groundbreaking research published in the INFORMS journal Information Systems Research highlights how a novel...